The invention relates to vaccines which are based on the molecular structure of human epithelial mucin, MUC1, for combating tumour cells which have remained in the body after surgery or another type of primary therapy (minimal residual disease). Said vaccines are characterised in that they carry O-glycosidically bonded a-N-acetylgalactosamine (GalNAc) or short-chained oligosaccharides on the threonine of the immunodominant region (amino acid sequence PDTRPAP). The inventive vaccines can be used in principle for all MUC1-positive carcinomas.
申请公布号
WO9934824(A3)
申请公布日期
1999.10.14
申请号
WO1998DE03819
申请日期
1998.12.30
申请人
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN;KARSTEN, UWE;HANISCH, FRANZ-GEORG;PAULSEN, HANS